System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Janus P Ong is an expert in Hepatology at Polytechnic University of the Philippines (Philippines). As of October 2026, ScienceLeadR ranks Janus P Ong in the top 1% of experts in the Philippines for MASH, Hepatitis and Liver Neoplasms. Janus P Ong has authored 127 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 416 (community average: 125). How the SLR is computed.

LeadR Profile

Janus P Ong Polytechnic University of the Philippines Philippines
416 ScienceLeadR Reputation 416

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1998 - 2026
Source: PubMed

Polytechnic University of the Philippines

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 127

Citations

Citations: 11 069 1st author: 30 Last author: 7 Unique author: 1

Main journals

J Hepatol 17
Gastroenterology 12
Clin Gastroenterol Hepatol 8
J Viral Hepat 6
Clin Liver Dis 5

Best Journals

Lancet Gastroenterol Hepatol 4
Gastroenterology 3
J Hepatol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Gender differences in stigma and care avoidance among people living with MASLD: an international survey.
PMID 42686023 — liver diseases, non-alcoholic fatty liver disease, liver, retention in care, sex characteristics, sex differences		JHEP Rep20260
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
PMID 42636832 — carcinoma, hepatocellular, progression-free survival, neoplasms, drug-related side effects and adverse reactions, therapeutics		Lancet Oncol Top journal20260
Response to Letter to the Editor on "Piloting eLearning initiatives: Computer-based training and telementoring for viral hepatitis care in public primary care setting".
PMID 42250805 — liver diseases, computers, hepatitis		Ann Hepatol20260
Special Population: Lean MASH.
PMID 42142902 — non-alcoholic fatty liver disease		Clin Liver Dis20260
Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.
PMID 41950980 — liver diseases, research design, fibrosis, non-alcoholic fatty liver disease, liver, therapeutics, liver stiffness, semaglutide		Clin Gastroenterol Hepatol20261

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2

By status:

Active not recruiting 1
Unknown 1

By type:

Interventional 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 2

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Evaluate Durvalumab and Tremelimumab Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842 — injections, carcinoma, hepatocellular, neoplasms, hepatic artery, arteries, liver, liver neoplasms, carcinoma		Phase 3Active not recruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS